Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-08-09
2009-12-29
Wehbe, Anne Marie S (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000
Reexamination Certificate
active
07638498
ABSTRACT:
A substance for preventing, delaying the onset of, or treating one or more than one autoimmune disease, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for the autoimmune disease. A method for preventing, delaying the onset of or treating an autoimmune disease in a patient comprising selecting a patient who is susceptible to developing the autoimmune disease, who is developing the autoimmune disease or who has the autoimmune disease and administering to the patient one or more than one dose of a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for an autoimmune disease, or comprising a polynucleotide sequence encoding the adenoviral protein E3-GP19k, or comprising a polynucleotide sequence encoding ΔBCL-2.
REFERENCES:
patent: WO 00/59538 (2000-12-01), None
Rabinovitch et al. (1999) Diabetes, vol. 48(6), 1223-1229.
Borner et al. (1994) J. Cell Biol., vol. 126(4) 1059-1068.
Allison et al. (2000) Int. Immunol., vol. 12(1), 9-17.
Strasser et al. (1991) PNAS, vol. 88, 8661-8665.
Mathisen and Touhy (2000) J. Clin. Immunol., vol. 20(5), 327-333.
Trucco et al. (2002) Curr. Gene Ther., vol. 2, 341-354.
Simone et al. (1999), Diabetes Care, vol. 22 (2), B7-B15.
EPO Search Report, Nov. 29, 2005.
Borner C. et al., J. Cell Biol., Aug. 1994, vol. 126, No. 4, pp. 1059-1068.
Contreras, Juan et al., Cytoprotection of Pancreatic Islets Before and Early After Transplantation Using Gene Therapy, Kidney International, Jan 2002, vol. 61, No. 1 Suppl., pp. 79-84.
Contreras, Juan et al., Gene Transfer of the BcI-2 Gene Confers Cytoprotection to Isolated Adult Porcine Pancreatic Islets Exposed to Xenoreactive Antibodies and Complement, Surgery, Aug. 2001, vol. 130, No. 2, pp. 166-174.
Efrat S. et al., Diabetes, May 2001, vol. 50, No. 5, pp. 980-984.
Filippova M. et al., Effects of Plasmid DNA Injection on Cyclophosphamide-Accelerated Diabetes in NOD Mice, DNA and Cell Biology, New York, NY, US vol. 20, No. 3, Mar. 1, 2001, pp. 175-181.
Ilan Y. et al., Proc. Natl. Acad. Sci. USA, Mar. 1997, vol. 94, pp. 2587-2592.
Li A. F. et al., Co-Delivery of Pro-Apoptotic BAX With a DNA Vaccine Recruits Dendritic Cells and Promotes Efficacy of Autoimmune Diabetes Prevention in Mice, Vaccine, Butterworth Scientific Guildford, GB, vol. 22, No. 13-14, Apr. 16, 2004, pp. 1751-1763.
Rabinovitch, A. et al., Diabetes, Jun. 1999, vol. 48, No. 6., pp. 1223-1229.
Tokui M. et al., Studies on the Prevention of Diabetes in NOD Mice by Intramuscular Adminstration of Plasmic Expressing GAD and IL-4, Chemical Abstracts + Indexes, American Chemical Society, Columbus, OH, US, vol. 25, No. 125, 1996, p. 1148.
Balasa, B. et al., “Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection,” Clin. Immunol., 2001, vol. 99, No. 2, pp. 241-252.
Chao, D. T. et al., BCL-2 family : regulators of cell death, Annu. Rev. Immunol., 1998, vol. 16, pp. 395-419.
Chattergoon, M. A., et al., “Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis,” Nat. Biotechnol., 2000, vol. 18, No. 9, pp. 974-979.
Chernysheva, A. D., el al., “T cell proliferation induced by autologous non-T cells is a response to apoptotic cells processed by dendritic cells,” J. Immunol., 2002, vol. 169, No. 3, pp. 1241-1250.
Restifo, N. P., “Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity,” Curr. Opin. Immunol., 2000, vol. 12, No. 5, pp. 597-603.
Sasaki, S. et al., “Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases,” Nat. Biotechnol., 2001, vol. 19, No. 6, pp. 543-547.
Tisch, R. et al., “Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination,” J. Immunol., 2001, vol. 166, No. 3, pp. 2122-2132.
Klinman, D. et al., “Use of CpG oligodeoxynucleotides as immune adjuvants,” Imm. Rev., 2004, vol. 199, pp. 201-216.
Krieg, Arthur M., “The role of CpG motifs in innate immunity,” Curr. Opin. Immun., 2000, vol. 12, pp. 35-43.
Li, Alice et al., “Co-delivery of pro-apoptotic BAX with a DNA vaccine recruits dendritic cells and promotes efficacy of autoimmune diabetes prevention in mice,” Vaccine 22 (2004) pp. 1751-1763.
Li, Alice et al., “Pro-apoptotic DNA vaccination ameliorates new onset of autoimmune diabetes in NOD mice and induces foxp3+ regulatory T cells in vitro,” Vaccine 24 (2006) pp. 5036-5046.
Scheule, R. K., “The role of CpG motifs in immunostimulation and gene therapy,” Adv. Drug Delivery Rev., 2000, vol. 44, pp. 119-134.
International Search Report and Written Opinion issued in related International Patent Application No. PCT/US06/17763 on Sep. 20, 2007.
Escher Alan P.
Li Fengchun
Farah David A.
Loma Linda University
Sheldon Mak Rose & Anderson
Wehbe Anne Marie S
LandOfFree
Substances for preventing and treating autoimmune diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substances for preventing and treating autoimmune diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substances for preventing and treating autoimmune diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4128790